The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 71.40
Bid: 69.00
Ask: 71.40
Change: 1.20 (1.74%)
Spread: 2.40 (3.478%)
Open: 72.00
High: 73.00
Low: 71.40
Prev. Close: 69.00
NCYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Total Voting Rights

1 Jun 2020 12:15

RNS Number : 5533O
Novacyt S.A.
01 June 2020
 

 

Liquidity Agreement Monthly Update andTotal Voting Rights

 

Paris, France and Camberley, UK - 1 June 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the "Liquidity Agreement"). The Liquidity Agreement is governed by French law and is further summarised in the 'notes for editors' section below.

 

During the period from 1 May to 31 May 2020, Invest Securities purchased 2,750 ordinary shares at a maximum price of €4.55 and a minimum price of €3.20 and sold 1,750 ordinary shares at a maximum price of €4.99 and a minimum price of €3.74 under the Liquidity Agreement. The total number of ordinary shares in the Company, which are held in treasury as at close of business on 31 May 2020, is 4,300.

 

Total Voting Rights

 

The total number of ordinary shares in the Company is 67,673,567. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company pursuant to Article L. 223-7 of the French Commercial Code and the Company's Articles. The Company is not subject to the disclosure guidance and transparency rules made by the Financial Conduct Authority under Part VI of FSMA.

 

 

For further information, please refer to www.novacyt.com or contact:

 

Novacyt SA

Graham Mullis, Chief Executive Officer

Anthony Dyer, Chief Financial Officer

+44 (0)1276 600081

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

FTI Consulting (International)

Victoria Foster Mitchell / Mary Whittow

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / mary.whittow@fticonsulting.com

 

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 47

arnaud.decheffontaines@fticonsulting.com 

 

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

 

For more information please refer to the website: www.novacyt.com

 

Further information on the Liquidity Agreement

On 12 September 2016, the Company and Invest Securities entered into the Liquidity Agreement pursuant to which Invest Securities provides liquidity services in relation to the ordinary shares to the Company. Invest Securities may purchase ordinary shares on behalf of the Company under the agreement, subject to approval from Shareholders as to the price at which ordinary shares can be brought back and the aggregate amount that the Company may provide to Invest Securities to purchase such ordinary shares.

 

Shareholder approval was granted at the Shareholders' meeting held on 27 June 2017 for the purchase of ordinary shares by Invest Securities under the agreement at a maximum purchase price per ordinary shares of €8.10 for an aggregate maximum purchase price of €100,000 and for 18 months from the date of the approval. Under the agreement, Invest Securities must act completely independently of the Company and the Company must not communicate with the employees of Invest Securities who are responsible for performing the agreement. Invest Securities is paid €10,000 per annum for its services under the liquidity agreement. The agreement has an initial term of two years, with a rolling extension of one year thereafter. The agreement can be terminated by either party at the end of each such period subject to two months' prior notice. The Liquidity Agreement is governed by French law. Ordinary shares purchased by Invest Securities are either cancelled or held as treasury shares (which are non-voting and do not rank for dividends).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVRUAVRRRKUNRAR
Date   Source Headline
5th Feb 202011:05 amRNSSecond Price Monitoring Extn
5th Feb 202011:00 amRNSPrice Monitoring Extension
3rd Feb 20204:45 pmRNSLiquidity Agreement and Total Voting Rights
3rd Feb 202011:05 amRNSSecond Price Monitoring Extn
3rd Feb 202011:00 amRNSPrice Monitoring Extension
3rd Feb 20209:00 amRNSPrice Monitoring Extension
31st Jan 20206:15 pmRNSExercise of Warrants and Issue of Equity
31st Jan 20207:00 amRNSLaunch of novel coronavirus test
28th Jan 20207:00 amRNSFull Year Trading and Operational Update
17th Jan 20207:00 amRNSPrimerdesign partners with VGS Group in France
2nd Jan 202010:30 amRNSLiquidity Agreement Update and Total Voting Rights
27th Dec 20197:00 amRNSCompletion of NOVAprep® business sale
2nd Dec 20192:16 pmRNSLiquidity Agreement and Total Voting Rights
6th Nov 20197:00 amRNSNew term loan and termination of bond facility
1st Nov 20191:30 pmRNSLiquidity Agreement and Total Voting Rights
7th Oct 20197:00 amRNSMolecular respiratory panel ready for US market
3rd Oct 20194:15 pmRNSConversion of Loan Notes
1st Oct 20192:30 pmRNSLiquidity Agreement and Total Voting Rights
27th Sep 20193:23 pmRNSConversion of Loan Notes
26th Sep 20197:00 amRNSHalf Year Results
25th Sep 20193:46 pmRNSConversion of Loan Notes
23rd Sep 20191:00 pmRNSConversion of Loan Notes
18th Sep 20192:45 pmRNSConversion of Loan Notes
12th Sep 20193:00 pmRNSConversion of Loan Notes
11th Sep 20195:00 pmRNSConversion of Loan Notes
2nd Sep 20191:00 pmRNSLiquidity Agreement and Total Voting Rights
28th Aug 20195:00 pmRNSConversion of Loan Notes
27th Aug 20197:00 amRNSConversion of Loan Notes
12th Aug 20194:45 pmRNSConversion of Loan Notes
7th Aug 201911:00 amRNSConversion of Loan Notes
2nd Aug 20193:00 pmRNSConversion of Loan Notes
2nd Aug 20192:00 pmRNSChange of Adviser
1st Aug 201910:45 amRNSLiquidity Agreement and Total Voting Rights
30th Jul 20197:00 amRNSHalf-Year Trading Update
19th Jul 20198:12 amRNSReplacement Result of AGM
19th Jul 20197:03 amRNSResult of AGM
18th Jul 20193:30 pmRNSSale of Clinical Lab
18th Jul 201911:00 amRNSConversion of Loan Notes
16th Jul 20194:30 pmRNSConversion of Loan Notes
9th Jul 20191:00 pmRNSConversion of Loan Notes
1st Jul 201911:00 amRNSLiquidity Agreement and Total Voting Rights
28th Jun 20194:00 pmRNSConversion of Loan Notes
26th Jun 201910:30 amRNSAnnual General Meeting Update
24th Jun 20194:15 pmRNSConversion of Loan Notes
21st Jun 20194:18 pmRNSConversion of Loan Notes
20th Jun 20191:55 pmRNSAnnual General Meeting Update
20th Jun 20191:55 pmRNSConversion of Loan Notes
19th Jun 20197:00 amRNSConversion of Loan Notes
14th Jun 20192:45 pmRNSConversion of Loan Notes
3rd Jun 20192:00 pmRNSLiquidity Agreement and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.